---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037596"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2026-08-13T12:23:31+00:00"
generated_at: "2026-08-13T12:25:08.911189+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics Q2 2026: $1.5M revenue, 2,770 EsoGuard tests, first LBM coverage policy

## Summary
- Q2 2026 EsoGuard revenue of $1.5M; 2,770 EsoGuard tests processed during the quarter.
- GAAP net loss ~$14.7M ($0.08/share) incl. $3.0M deemed preferred stock dividend; non-GAAP adjusted loss ~$10.9M ($0.06/share).
- Operating expenses ~$14.3M, including $1.7M stock-based compensation; cash $33.4M at June 30, 2026 vs $34.7M at Dec 31, 2025.
- Secured first laboratory benefit manager coverage policy from Concert (acquired by Lyric) recognizing EsoGuard as medically necessary for eligible patients.
- Developed health economic model showing improved clinical outcomes and cost-effectiveness; awaiting draft Medicare coverage policy for EsoGuard.

## SEC filing metadata
- accession: 0001493152-26-037596
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2026-08-13T12:23:31+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315226037596/0001493152-26-037596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315226037596/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037596
- JSON: https://secwatch.observer/filing/0001493152-26-037596.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037596.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.